Galapagos enters into global alliance with Janssen Pharmaceutica on rheumatoid arthritis research
Multi-target alliance to discover, develop, and commercialize oral small molecule therapeutics for rheumatoid arthritis
25-Oct-2007 -
Galapagos NV announced that it has entered into a worldwide multi-target alliance with Janssen Pharmaceutica NV, a Johnson & Johnson company, to discover and develop novel
small-molecule therapeutics for the treatment of rheumatoid arthritis (RA). Under the alliance agreement, Janssen may select ...
clinical trials
Galapagos
Johnson & Johnson
+2